DK2477649T3 - Vaccine mod kolera og enterotoksigen e.coli (etec) - diarré - Google Patents
Vaccine mod kolera og enterotoksigen e.coli (etec) - diarré Download PDFInfo
- Publication number
- DK2477649T3 DK2477649T3 DK10817520.9T DK10817520T DK2477649T3 DK 2477649 T3 DK2477649 T3 DK 2477649T3 DK 10817520 T DK10817520 T DK 10817520T DK 2477649 T3 DK2477649 T3 DK 2477649T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- ogawa
- vaccine
- inaba
- wbet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Vaccine indeholdende en Vibrio cholerae 01-celle, kendetegnet ved, at cellen indeholder 01-antigener af både Ogawa- og Inaba-serotyper, hvor vaccinen omfatter flere Vibrio cholerae 01-celler, der indeholder 01-antigener af både Ogawa- og Inaba-serotyper, og hvor gennemsnitligt 10-90 % af 01-antigenerne af cellerne er af Ogawa-serotypen.
2. Vaccine ifølge ethvert af de foregående krav, med det forbehold, at vaccinen ikke indeholder nogen yderligere immunologisk aktive hele celler ud over Vibrio cholerae 01-celler, der indeholder 01-antigener af både Ogawa- og Inaba-serotyper.
3. Vaccine ifølge ethvert af de foregående krav, hvor vaccinen er beregnet til oral indgivelse.
4. Vaccine ifølge ethvert af de foregående krav, i hvilken cellen er formalin-inaktiveret.
5. Vaccine ifølge ethvert af de foregående krav, i hvilken cellen er som defineret i ethvert af kravene 10-11.
6. Vaccine ifølge ethvert af de foregående krav til anvendelse ved præventiv immunisering.
7. Vaccine ifølge ethvert af de foregående krav til anvendelse ved præventiv immunisering mod kolera.
8. Vaccine ifølge ethvert af de foregående krav, i hvilken cellen yderligere indeholder ét eller flere ETEC-koloniseringsfaktor (CF)-proteiner, såsom CFA/I, CS2 eller CS5, hvor CF-proteinet/proteinerne udtrykkes enten som enkelte, dobbelte eller hybridfimbrier.
9. Vaccine ifølge krav 8 til anvendelse ved præventiv immunisering mod enterotoksigen Escherichia coli-infektion (ETEC).
10. Vibrio cholerae 01 -celle, der samtidigt udtrykker både Inaba- og Ogawa-antigener, kendetegnet ved, at a. cellen indeholder et endogent wbeT-gen; og b. cellen indeholder et rekombinant DNA-konstrukt, der kan modulere ekspressionsniveauet af endogent wbeT-gen eller den enzymatiske aktivitet af produktet deraf; hvor konstruktet er egnet til at modificere det endogene wbeT-gen i værtsorganismen ved hjælp af homolog rekombination, og hvor c. det modulerede niveau af wbeT-enzymaktivitet er således, at cellen samtidigt udtrykker Inaba- og Ogawa-antigener, hvor 10-90 % af 01-antigenet udtrykt af cellen er af Ogawa-serotypen.
11. Vibrio cholerae 01-celle ifølge krav 10, hvor cellen yderligere udtrykker ét eller flere ETEC-koloniseringsfaktor (CF)-proteiner, såsom CFA/I, CS2 eller CS5, hvor CF-proteinet/proteinerne udtrykkes enten som enkelte, dobbelte eller hybrid-fimbrier.
12. Fremgangsmåde til fremstilling af en vaccine, omfattende trinene: a. tilvejebringelse af en Vibrio cholerae 01-celle indeholdende 01-antigener af både Ogawa- og Inaba-serotyper; og b. drab af cellen.
13. Fremgangsmåde ifølge krav 12, ved hvilken drabet udføres ved formalinbehandling.
14. Fremgangsmåde ifølge ethvert af kravene 12-13, ved hvilken cellen er en celle ifølge ethvert af kravene 10-11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27235109P | 2009-09-16 | 2009-09-16 | |
| PCT/SE2010/050996 WO2011034495A1 (en) | 2009-09-16 | 2010-09-16 | Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2477649T3 true DK2477649T3 (da) | 2017-03-06 |
Family
ID=43758898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10817520.9T DK2477649T3 (da) | 2009-09-16 | 2010-09-16 | Vaccine mod kolera og enterotoksigen e.coli (etec) - diarré |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9511133B2 (da) |
| EP (1) | EP2477649B1 (da) |
| JP (2) | JP2013505017A (da) |
| KR (1) | KR101722802B1 (da) |
| CN (1) | CN102630166B (da) |
| AU (1) | AU2010296065B2 (da) |
| CA (1) | CA2774335C (da) |
| DK (1) | DK2477649T3 (da) |
| ES (1) | ES2616912T3 (da) |
| HU (1) | HUE031957T2 (da) |
| IN (1) | IN2012DN02860A (da) |
| PL (1) | PL2477649T3 (da) |
| PT (1) | PT2477649T (da) |
| WO (1) | WO2011034495A1 (da) |
| ZA (1) | ZA201202710B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| CN102824632A (zh) * | 2012-09-12 | 2012-12-19 | 北京民海生物科技有限公司 | 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用 |
| RU2535122C1 (ru) * | 2013-11-06 | 2014-12-10 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения холерогена-анатоксина |
| RU2563620C2 (ru) * | 2014-08-05 | 2015-09-20 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения таблетированной формы холерной бивалентной химической вакцины |
| EP3390646A4 (en) * | 2015-12-14 | 2019-10-30 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | NOVEL METHOD FOR THE PRODUCTION OF CLEANED RECOMBINANT CHOLERATOXIN B (RCTB) AND FORMULATION THEREOF |
| US10829522B2 (en) | 2016-04-27 | 2020-11-10 | Osaka University | Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same |
| US20210085775A1 (en) | 2017-12-15 | 2021-03-25 | Valneva Sweden Ab | Methods and composition for preventing and/or treating cancer |
| WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
| WO2021105061A1 (en) | 2019-11-25 | 2021-06-03 | Gotovax Ab | Whole cell vaccines and methods of production thereof |
| US20230372464A1 (en) | 2020-10-07 | 2023-11-23 | Valneva Sweden Ab | Cholera vaccine formulation |
| WO2022117823A1 (en) | 2020-12-04 | 2022-06-09 | Valneva Se | Methods and compositions for preventing and/or treating autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882653A (en) | 1983-03-04 | 1999-03-16 | The University Of Maryland System | Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof |
| US5330753A (en) * | 1987-04-29 | 1994-07-19 | President And Fellows Of Harvard College | Cholera vaccines |
| ATE242319T1 (de) * | 1992-07-06 | 2003-06-15 | Harvard College | Deletionsmutanten als impfstoffe gegen cholera |
| US6203799B1 (en) | 1993-07-01 | 2001-03-20 | Presidents And Fellows Of Harvard College | Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit |
| JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| WO2000067784A1 (en) | 1999-05-10 | 2000-11-16 | University Of Maryland, Baltimore | Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof |
| US7270961B2 (en) | 2002-04-16 | 2007-09-18 | Hui Sunny Chang | In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes |
| WO2004020406A2 (en) * | 2002-08-30 | 2004-03-11 | International Centre For Diarrhoeal Disease Research | Variants of vibrio cholerae o1 biotype e1 tor with attributes of classical biotype |
| CU23334A1 (es) * | 2003-03-20 | 2008-12-24 | Inst Finlay | Vacuna de vibrio cholerae inactivada en tabletas |
| US20060099229A1 (en) | 2004-11-05 | 2006-05-11 | Universiti Sains Malaysia | Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof |
| EP1543836A1 (en) * | 2003-12-17 | 2005-06-22 | Berna Biotech AG | Recombinant Vibrio cholerae strain and vaccine comprising said strain |
| WO2009049013A2 (en) * | 2007-10-09 | 2009-04-16 | Tufts University | Cholera vaccines |
-
2010
- 2010-09-16 US US13/496,183 patent/US9511133B2/en active Active
- 2010-09-16 IN IN2860DEN2012 patent/IN2012DN02860A/en unknown
- 2010-09-16 HU HUE10817520A patent/HUE031957T2/en unknown
- 2010-09-16 AU AU2010296065A patent/AU2010296065B2/en active Active
- 2010-09-16 JP JP2012529714A patent/JP2013505017A/ja active Pending
- 2010-09-16 PT PT108175209T patent/PT2477649T/pt unknown
- 2010-09-16 EP EP10817520.9A patent/EP2477649B1/en active Active
- 2010-09-16 PL PL10817520T patent/PL2477649T3/pl unknown
- 2010-09-16 CA CA2774335A patent/CA2774335C/en active Active
- 2010-09-16 KR KR1020127009647A patent/KR101722802B1/ko active IP Right Grant
- 2010-09-16 DK DK10817520.9T patent/DK2477649T3/da active
- 2010-09-16 ES ES10817520.9T patent/ES2616912T3/es active Active
- 2010-09-16 CN CN201080041458.1A patent/CN102630166B/zh active Active
- 2010-09-16 WO PCT/SE2010/050996 patent/WO2011034495A1/en active Application Filing
-
2012
- 2012-04-13 ZA ZA2012/02710A patent/ZA201202710B/en unknown
-
2015
- 2015-11-20 JP JP2015227296A patent/JP6178384B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2477649T (pt) | 2017-03-01 |
| US9511133B2 (en) | 2016-12-06 |
| ES2616912T3 (es) | 2017-06-14 |
| AU2010296065B2 (en) | 2015-05-21 |
| AU2010296065A1 (en) | 2012-05-10 |
| EP2477649B1 (en) | 2016-11-23 |
| KR20120081600A (ko) | 2012-07-19 |
| EP2477649A1 (en) | 2012-07-25 |
| JP2013505017A (ja) | 2013-02-14 |
| IN2012DN02860A (da) | 2015-06-19 |
| KR101722802B1 (ko) | 2017-04-03 |
| US20120276146A1 (en) | 2012-11-01 |
| JP2016074695A (ja) | 2016-05-12 |
| CN102630166B (zh) | 2015-08-05 |
| WO2011034495A1 (en) | 2011-03-24 |
| EP2477649A4 (en) | 2013-01-30 |
| JP6178384B2 (ja) | 2017-08-09 |
| HUE031957T2 (en) | 2017-09-28 |
| CN102630166A (zh) | 2012-08-08 |
| ZA201202710B (en) | 2015-12-23 |
| PL2477649T3 (pl) | 2017-06-30 |
| CA2774335A1 (en) | 2011-03-24 |
| CA2774335C (en) | 2016-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2477649T3 (da) | Vaccine mod kolera og enterotoksigen e.coli (etec) - diarré | |
| CZ20011538A3 (cs) | Nezávisle fungující expresní kazeta, amplifikovatelný plazmidový replikon, bakteriální buňka, vakcinační vektor, podmíněně nestabilní plazmid, způsob vyvolání imunitní odpovědi, DNA a expresní plazmid | |
| AU2023251424A1 (en) | Engineered viral vector reduces induction of inflammatory and immune responses | |
| EA024036B1 (ru) | Рекомбинантный ген m вируса гриппа b, кодирующий белок m1 с мутацией m86v | |
| KR102014518B1 (ko) | HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신 | |
| SA519401615B1 (ar) | لقاح dna مُولِد للتحمل | |
| AU2002321652B2 (en) | Attenuated bacteria useful in vaccines | |
| CN112867798A (zh) | 用于治疗半乳糖血症的基因疗法 | |
| JP2014509513A (ja) | ヘリコバクター・ピロリにおける遺伝子発現および除菌システム | |
| Yan et al. | Asd-based balanced-lethal system in attenuated Edwardsiella tarda to express a heterologous antigen for a multivalent bacterial vaccine | |
| EA011282B1 (ru) | Бактериальные упаковывающие штаммы, используемые для генерирования и продуцирования рекомбинантных нуклеокапсидов с двухцепочечной рнк, и их применение | |
| US20040028695A1 (en) | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis | |
| US11679149B2 (en) | Immunogenic compositions | |
| CN111088201B (zh) | 一株重组丙酮丁醇梭菌及其构建方法与应用 | |
| KR102079761B1 (ko) | pMyong2 벡터 시스템을 이용하여 HIV-1 p24를 발현하는 재조합 BCG 및 이의 HIV-1 백신으로의 이용 | |
| JP2004510745A (ja) | 細菌におけるプラスミド遺伝の安定化 | |
| CN109136160B (zh) | 一种2-甲基柠檬酸高产基因工程菌及其构建方法 | |
| Malik et al. | Silencing Transcription from an Influenza Reverse Genetics Plasmid in E. coli Enhances Gene Stability | |
| CN101220371B (zh) | 重组双歧杆菌hRV-VP4表达载体及其口服疫苗 | |
| TW201736597A (zh) | 用於流感病毒的減弱活疫苗 | |
| KR20230173145A (ko) | 심각한 질병을 치료하기 위한 b 세포 기반 단백질 공장 조작 | |
| NM et al. | Construction of a Vector for the Constitutive Expression of Human Papilloma Virus type 16 Genes in Salmonella Enterica Serovar Typhi Strain Ty21a | |
| CN106518991A (zh) | 鸭疫里默氏杆菌血清1型铁载体受体蛋白srp及其基因工程突变菌株的构建方法 | |
| Morin | Development of new tools for foreign antigen expression in live Vibrio cholerae vaccine strains |